[en] Balanced activity of kinases and phosphatases downstream of the BCR is essential for B cell differentiation and function and is disturbed in chronic lymphocytic leukemia (CLL). In this study, we employed IgH.TEμ mice, which spontaneously develop CLL, and stable EMC CLL cell lines derived from these mice to explore the role of phosphatases in CLL. Genome-wide expression profiling comparing IgH.TEμ CLL cells with wild-type splenic B cells identified 96 differentially expressed phosphatase genes, including SH2-containing inositol phosphatase (Ship2). We found that B cell-specific deletion of Ship2, but not of its close homolog Ship1, significantly reduced CLL formation in IgH.TEμ mice. Treatment of EMC cell lines with Ship1/2 small molecule inhibitors resulted in the induction of caspase-dependent apoptosis. Using flow cytometry and Western blot analysis, we observed that blocking Ship1/2 abrogated EMC cell survival by exerting dual effects on the BCR signaling cascade. On one hand, specific Ship1 inhibition enhanced calcium signaling and thereby abrogated an anergic response to BCR stimulation in CLL cells. On the other hand, concomitant Ship1/Ship2 inhibition or specific Ship2 inhibition reduced constitutive activation of the mTORC1/ribosomal protein S6 pathway and downregulated constitutive expression of the antiapoptotic protein Mcl-1, in both EMC cell lines and primary IgH.TEμ CLL cells. Importantly, also in human CLL, we found overexpression of many phosphatases including SHIP2. Inhibition of SHIP1/SHIP2 reduced cellular survival and S6 phosphorylation and enhanced basal calcium levels in human CLL cells. Taken together, we provide evidence that SHIP2 contributes to CLL pathogenesis in mouse and human CLL.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Pal Singh, Simar
de Bruijn, Marjolein J. W.
Velaso Gago da Graça, Catarina
Cornet, Odilia B. J.
Rip, Jasper
Stadhouders, Ralph
Meijers, Ruud W. J.
Schurmans, Stéphane ; Université de Liège - ULiège > Département des sciences fonctionnelles (DSF) > Biochimie métabolique vétérinaire
Pal Singh, S., Dammeijer, F., Hendriks, R.W., Role of bruton’s tyrosine kinase in b cells and malignancies (2018) Mol. Cancer, 17, p. 57. , Published erratum 2019 Mol. Cancer 18: 79
Müschen, M., Autoimmunity checkpoints as therapeutic targets in b cell malignancies (2018) Nat. Rev. Cancer, 18, pp. 103-116
Hendriks, R.W., Yuvaraj, S., Kil, L.P., Targeting bruton’s tyrosine kinase in b cell malignancies (2014) Nat. Rev. Cancer, 14, pp. 219-232
Byrd, J.C., Harrington, B., O’Brien, S., Jones, J.A., Schuh, A., Devereux, S., Chaves, J., Brown, J.R., Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia (2016) N. Engl. J. Med., 374, pp. 323-332
Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Wierda, W.G., Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia (2013) N. Engl. J. Med., 369, pp. 32-42
Burger, J.A., Tedeschi, A., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Li, J., Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia (2015) N. Engl. J. Med., 373, pp. 2425-2437
Brown, J.R., Byrd, J.C., Coutre, S.E., Benson, D.M., Flinn, I.W., Wagner-Johnston, N.D., Spurgeon, S.E., Webb, H.K., Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/ refractory chronic lymphocytic leukemia (2014) Blood, 123, pp. 3390-3397
Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., Barrientos, J.C., Flinn, I., Idelalisib and rituximab in relapsed chronic lymphocytic leukemia (2014) N. Engl. J. Med., 370, pp. 997-1007
Manning, B.D., Toker, A., AKT/PKB signaling: Navigating the network (2017) Cell, 169, pp. 381-405
Mockridge, C.I., Potter, K.N., Wheatley, I., Neville, L.A., Packham, G., Stevenson, F.K., Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status (2007) Blood, 109, pp. 4424-4431
Singh, S.P., Pillai, S.Y., de Bruijn, M.J.W., Stadhouders, R., Corneth, O.B.J., van den Ham, H.J., Muggen, A., Kuil, A., Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive btk and akt signaling (2017) Oncotarget, 8, pp. 71981-71995
Dühren-Von Minden, M., Übelhart, R., Schneider, D., Wossning, T., Bach, M.P., Buchner, M., Hofmann, D., Köhler, F., Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling (2012) Nature, 489, pp. 309-312
Stamatopoulos, K., Agathangelidis, A., Rosenquist, R., Ghia, P., Antigen receptor stereotypy in chronic lymphocytic leukemia (2017) Leukemia, 31, pp. 282-291
ter Brugge, P.J., Ta, V.B., de Bruijn, M.J., Keijzers, G., Maas, A., van Gent, D.C., Hendriks, R.W., A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large t antigen (2009) Blood, 114, pp. 119-127
Yu, Y., Alwine, J.C., Human cytomegalovirus major immediate-early proteins and simian virus 40 large t antigen can inhibit apoptosis through activation of the phosphatidylinositide 39-OH kinase pathway and the cellular kinase akt (2002) J. Virol., 76, pp. 3731-3738
Laine, J., Künstle, G., Obata, T., Sha, M., Noguchi, M., The protooncogene TCL1 is an akt kinase coactivator (2000) Mol. Cell, 6, pp. 395-407
Wang, J.W., Howson, J.M., Ghansah, T., Desponts, C., Ninos, J.M., May, S.L., Nguyen, K.H., Kerr, W.G., Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation (2002) Science, 295, pp. 2094-2097
Dubois, E., Jacoby, M., Blockmans, M., Pernot, E., Schiffmann, S.N., Foukas, L.C., Henquin, J.C., Schurmans, S., Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel ship2 mutant mouse (2012) Cell. Signal., 24, pp. 1971-1980
Hobeika, E., Thiemann, S., Storch, B., Jumaa, H., Nielsen, P.J., Pelanda, R., Reth, M., Testing gene function early in the b cell lineage in mb1-cre mice (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 13789-13794
Gumbleton, M., Sudan, R., Fernandes, S., Engelman, R.W., Russo, C.M., Chisholm, J.D., Kerr, W.G., Dual enhancement of t and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival (2017) Sci. Signal., 10
Suwa, A., Yamamoto, T., Sawada, A., Minoura, K., Hosogai, N., Tahara, A., Kurama, T., Aramori, I., Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2 (2009) Br. J. Pharmacol., 158, pp. 879-887
Ho, T.T., Warr, M.R., Adelman, E.R., Lansinger, O.M., Flach, J., Verovskaya, E.V., Figueroa, M.E., Passegué, E., Autophagy maintains the metabolism and function of young and old stem cells (2017) Nature, 543, pp. 205-210
Kil, L.P., de Bruijn, M.J., van Nimwegen, M., Corneth, O.B., van Hamburg, J.P., Dingjan, G.M., Thaiss, F., Delsing, D., Btk levels set the threshold for B-cell activation and negative selection of autoreactive b cells in mice (2012) Blood, 119, pp. 3744-3756
Robinson, M.D., McCarthy, D.J., Smyth, G.K., Edger: A bioconductor package for differential expression analysis of digital gene expression data (2010) Bioinformatics, 26, pp. 139-140
Pal Singh, S., de Bruijn, M.J.W., de Almeida, M.P., Meijers, R.W.J., Nitschke, L., Langerak, A.W., Pillai, S.Y., Hendriks, R.W., Identification of distinct unmutated chronic lymphocytic leukemia subsets in mice based on their t cell dependency (2018) Front. Immunol., 9, p. 1996
Heng, T.S., Painter, M.W., The immunological genome project: Networks of gene expression in immune cells (2008) Nat. Immunol., 9, pp. 1091-1094
Hallaert, D.Y., Spijker, R., Jak, M., Derks, I.A., Alves, N.L., Wensveen, F.M., de Boer, J.P., Eldering, E., Crosstalk among bcl-2 family members in B-CLL: Seliciclib acts via the mcl-1/ noxa axis and gradual exhaustion of bcl-2 protection (2007) Cell Death Differ, 14, pp. 1958-1967
Negro, R., Gobessi, S., Longo, P.G., He, Y., Zhang, Z.Y., Laurenti, L., Efremov, D.G., Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT (2012) Blood, 119, pp. 6278-6287
Schliffke, S., Buhs, S., Bolz, S., Gerull, H., von Wenserski, L., Riecken, K., Fehse, B., Binder, M., The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia (2018) Blood, 131, pp. 1755-1758
Johnston, H.E., Carter, M.J., Larrayoz, M., Clarke, J., Garbis, S.D., Oscier, D., Strefford, J.C., Cragg, M.S., Proteomics profiling of CLL versus healthy b-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation (2018) Mol. Cell. Proteomics, 17, pp. 776-791
Li, H., Wu, X., Hou, S., Malek, M., Kielkowska, A., Noh, E., Makondo, K.J., Johnston, J.B., Phosphatidylinositol-3,4-bisphosphate and its binding protein lamellipodin regulate chemotaxis of malignant b lymphocytes (2016) J. Immunol., 196, pp. 586-595
Gabelloni, M.L., Borge, M., Galletti, J., Cañones, C., Fernández Calotti, P., Bezares, R.F., Avalos, J.S., Gamberale, R., SHIP-1 protein level and phosphorylation status differs between CLL cells segregated by ZAP-70 expression (2008) Br. J. Haematol., 140, pp. 117-119
Akerlund, J., Getahun, A., Cambier, J.C., B cell expression of the SH2-containing inositol 5-phosphatase (SHIP-1) is required to establish anergy to high affinity, proteinacious autoantigens (2015) J. Autoimmun., 62, pp. 45-54
Fuhler, G.M., Brooks, R., Toms, B., Iyer, S., Gengo, E.A., Park, M.Y., Gumbleton, M., Kerr, W.G., Therapeutic potential of SH2 domain-containing inositol-59-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer (2012) Mol. Med., 18, pp. 65-75
Leung, W.H., Tarasenko, T., Biesova, Z., Kole, H., Walsh, E.R., Bolland, S., Aberrant antibody affinity selection in SHIP-deficient b cells (2013) Eur. J. Immunol., 43, pp. 371-381
Liu, Q., Oliveira-Dos-Santos, A.J., Mariathasan, S., Bouchard, D., Jones, J., Sarao, R., Kozieradzki, I., Dumont, D.J., The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of b cell antigen receptor signaling (1998) J. Exp. Med., 188, pp. 1333-1342
van Attekum, M.H.A., Terpstra, S., Slinger, E., von Lindern, M., Moerland, P.D., Jongejan, A., Kater, A.P., Eldering, E., Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia (2017) Oncogene, 36, pp. 3651-3660
Brooks, R., Fuhler, G.M., Iyer, S., Smith, M.J., Park, M.Y., Paraiso, K.H., Engelman, R.W., Kerr, W.G., SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells (2010) J. Immunol., 184, pp. 3582-3589
Hoekstra, E., Das, A.M., Willemsen, M., Swets, M., Kuppen, P.J., van der Woude, C.J., Bruno, M.J., Chisholm, J.D., Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation (2016) Oncotarget, 7, pp. 73525-73540
Cheng, S., Ma, J., Guo, A., Lu, P., Leonard, J.P., Coleman, M., Liu, M., Wang, Y.L., BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity (2014) Leukemia, 28, pp. 649-657
Kerr, W.G., Inhibitor and activator: Dual functions for SHIP in immunity and cancer (2011) Ann. N. Y. Acad. Sci., 1217, pp. 1-17
Sharma, A., Janocha, A.J., Hill, B.T., Smith, M.R., Erzurum, S.C., Almasan, A., Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant b cells (2014) Mol. Cancer Res., 12, pp. 1205-1215
Davids, M.S., Brown, J.R., Targeting the b cell receptor pathway in chronic lymphocytic leukemia (2012) Leuk. Lymphoma, 53, pp. 2362-2370
Cosimo, E., Tarafdar, A., Moles, M.W., Holroyd, A.K., Malik, N., Catherwood, M.A., Hay, J., Guichard, S.M., AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B-cell receptor-mediated survival (2019) Clin. Cancer Res., 25, pp. 1574-1587
Chen, Z., Shojaee, S., Buchner, M., Geng, H., Lee, J.W., Klemm, L., Titz, B., Tan, Y.X., Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia (2015) Nature, 521, pp. 357-361. , Published erratum 2016 Nature 534: 138
Bolland, S., Pearse, R.N., Kurosaki, T., Ravetch, J.V., SHIP modulates immune receptor responses by regulating membrane association of btk (1998) Immunity, 8, pp. 509-516
Damen, J.E., Liu, L., Rosten, P., Humphries, R.K., Jefferson, A.B., Majerus, P.W., Krystal, G., The 145-kda protein induced to associate with shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase (1996) Proc. Natl. Acad. Sci. USA, 93, pp. 1689-1693
Lückhoff, A., Clapham, D.E., Inositol 1,3,4,5-tetrakisphosphate activates an endothelial ca(2+)-permeable channel (1992) Nature, 355, pp. 356-358
Okada, H., Bolland, S., Hashimoto, A., Kurosaki, M., Kabuyama, Y., Iino, M., Ravetch, J.V., Kurosaki, T., Role of the inositol phosphatase SHIP in b cell receptor-induced ca2+ oscillatory response (1998) J. Immunol., 161, pp. 5129-5132
Pesesse, X., Moreau, C., Drayer, A.L., Woscholski, R., Parker, P., Erneux, C., The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity (1998) FEBS Lett, 437, pp. 301-303
Jerkeman, M., Hallek, M., Dreyling, M., Thieblemont, C., Kimby, E., Staudt, L., Targeting of B-cell receptor signalling in B-cell malignancies (2017) J. Intern. Med., 282, pp. 415-428
Kerr, W.G., Brooks, R., Park, M.-Y., Gumbleton, M., Iyer, S., Viernes, D., Chisholm, J., Fuhler, G.M., Abstract c81: Therapeutic potential of SHIP1 and SHIP2 inhibitors in cancer (2011) Mol. Cancer Ther., 10